

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study.

For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|----------------------------------|---|
| ☒ | ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☒ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☒ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☒ | ☒ A description of all covariates tested |
| ☒ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☐ |
| ☒ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☒ | ☒ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☒ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☒ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☒ | ☒ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	CHI 660e and Origin 9.0
Data analysis	CHI 660e is a electrochemical test and analysis software, which was used to collected all the electrochemical data in this manuscript. Origin 9.0 is

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data that support the findings of this study are openly available in figshare at <https://pubs.acs.org/doi/10.1021/ja2058617>, reference number 59; <https://pubs.acs.org/doi/10.1021/acscentsci.0c01262>, Reference Number 60; <https://onlinelibrary.wiley.com/doi/10.1002/anie.202116179>, Reference Number 28; <https://onlinelibrary.wiley.com/doi/full/10.1002/aenm.202201478>, Reference Number 65; <https://www.chinesechemsoc.org/doi/10.31635/ccschem.022.202202451>, Reference Number 68.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	This information has not been collected.
Population characteristics	This information has not been collected.
Recruitment	This manuscript is not related with recruitment.
Ethics oversight	This Protocol is not involve the ethics oversight.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☐ Life sciences ☐ Behavioural & social sciences ☒ Ecological, evolutionary & environmental sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	
Data exclusions	
Replication	
Randomization	
Blinding	

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	
Research sample	
Sampling strategy	
Data collection	
Timing	
Data exclusions	
Non-participation	
Randomization	

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	This Protocol describes how to prepare ordered mesoporous intermetallic nanomaterials with controlled compositions.
Research sample	The samples of ordered mesoporous intermetallic nanomaterials are the Research Samples, which contain: mesoporous Pt/Pd based
Sampling strategy	The synthetic strategy is the concurrent template strategy, which using the mesoporous Pt/Pd nanocrystals confined in hard silica
Data collection	All the data are collected by equipments based on the suitable experiments conditions which have been described in the manuscript. All
Timing and spatial scale	As shown in the manuscript, the data can be collected in only 5 days, but the discovery timing is longer than this, we have started this

Data exclusions	No data are excluded from the analyses.
Reproducibility	All the experiments based on synthetic details could be synthesized successfully.
Randomization	This is not relevant to our study. Chemical synthesis and catalysis could be well controlled all the reaction conditions.
Blinding	The blinding is not relevant to our study. Because all of the study is about the nanosynthetic method of mesoporous intermetallic
Did the study involve field work? ☐ Yes ☒ No	

Field work, collection and transport

Field conditions	
Location	
Access & import/export	
Disturbance	

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods
n/a Involved in the study ☒ Antibodies ☒ Eukaryotic cell lines ☒ Palaeontology and archaeology ☒ Animals and other organisms ☒ Clinical data ☒ Dual use research of concern	n/a Involved in the study ☒ ChIP-seq ☒ Flow cytometry ☒ MRI-based neuroimaging

Antibodies

Antibodies used	
Validation	

Eukaryotic cell lines

Policy information about [cell lines](#) and [Sex and Gender in Research](#)

Cell line source(s)	
Authentication	
Mycoplasma contamination	
Commonly misidentified lines (See ICLAC register)	

Palaeontology and Archaeology

Specimen provenance	
Specimen deposition	
Dating methods	
☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.	
Ethics oversight	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about [studies involving animals](#); ARRIVE [guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	
Wild animals	
Reporting on sex	
Field-collected samples	
Ethics oversight	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)
All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	
Study protocol	
Data collection	
Outcomes	

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes
☐	☒ Public health
☐	☒ National security
☐	☒ Crops and/or livestock
☐	☒ Ecosystems
☐	☒ Any other significant area

Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
☐	☒ Demonstrate how to render a vaccine ineffective
☐	☒ Confer resistance to therapeutically useful antibiotics or antiviral agents
☐	☒ Enhance the virulence of a pathogen or render a nonpathogen virulent
☐	☒ Increase transmissibility of a pathogen
☐	☒ Alter the host range of a pathogen
☐	☒ Enable evasion of diagnostic/detection modalities
☐	☒ Enable the weaponization of a biological agent or toxin
☐	☒ Any other potentially harmful combination of experiments and agents

ChIP-seq

Data deposition

- ☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links	
-------------------	----------------------

May remain private before publication

Files in database submission

Genome browser session
(e.g. [UCSC](#))

Methodology

Replicates

Sequencing depth

Antibodies

Peak calling parameters

Data quality

Software

Flow Cytometry

Plots

Confirm that:

☐The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

☐The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

☐All plots are contour plots with outliers or pseudocolor plots.

☐A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Instrument

Software

Cell population abundance

Gating strategy

☐Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type

Design specifications

Behavioral performance measures

Acquisition

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI

☒Used

☐Not used

Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis:

☐ Whole brain ☐ ROI-based ☐ Both

Statistic type for inference
(See [Eklund et al. 2016](#))

Correction

Models & analysis

n/a

Involved in the study

☐ Functional and/or effective connectivity

☐ Graph analysis

☐ Multivariate modeling or predictive analysis

Functional and/or effective connectivitv

Graph analysis

Multivariate modeling and predictive analysis



